US6042610A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Meniscal augmentation device
Assignee: Regen Biologics Inc
•
Filing: 1998-02-24
•
Granted: 2000-03-28
•
Expires: 2018-02-24
Abstract
Abstract The present invention relates to a meniscal augmentation device of biocompatible and at least partially bioresorbable fibers for implantation into a segmental defect of a meniscus in a subject. Upon implantation, the composite of the device and the meniscus establishes a scaffold adapted for ingrowth of meniscal fibrochondrocytes. The invention further pertains to methods of fabricating and using the device.
Inventors
- 👤 Shu-Tung Li
- 👤 Kevin R. Stone
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 21:59
CPC Classifications
A; A61; A61L; A61L27/00; A61L27/50; A61L27/58; A61F; A61F2/00; A61F2/02; A61F2/28; A61F2/30; A61F2/30721; A61F2/30734; A61F2/30756; A61F2/38; A61F2/3872; A61F2/42; A61F2/4261; A61F2/44; A61F2/442; A61L27/14; A61L27/20; A61L27/22; A61L27/227; A61L27/24; A61L27/26; A61L27/36; A61L27/3641; A61L27/40; A61L27/44; A61L27/46; A61L27/48; A61L27/54; A61L27/56; A61P; A61P19/00; A61P19/02; A61B; A61B17/00; A61B17/04; A61B17/0469; A61F2/30767; A61F2/30907; A61F2/3094; A61F2/30965; A61F2/46; A61F2/4603; A61F2/461; A61F2002/30001; A61F2002/30003; A61F2002/3006; A61F2002/30062; A61F2002/30108; A61F2002/3011; A61F2002/30112; A61F2002/30113; A61F2002/30131; A61F2002/30199; A61F2002/30205; A61F2002/30224; A61F2002/30225; A61F2002/3023; A61F2002/30667; A61F2002/30677; A61F2002/30736; A61F2002/30766; A61F2/30771; A61F2002/30795; A61F2002/30807; A61F2002/30808; A61F2002/3082; A61F2002/30822; A61F2002/30827; A61F2002/30878; A61F2002/30879; A61F2002/30881; A61F2002/30891; A61F2002/30904; A61F2/30942; A61F2002/30957; A61F2002/4271; A61F2002/4274; A61F2002/4276; A61F2002/4279; A61F2002/4282; A61F2002/4284; A61F2002/4287; A61F2002/4289; A61F2002/4292; A61F2002/4294; A61F2002/4297; A61F2002/4495; A61F2210/00; A61F2210/0004; A61F2230/00; A61F2230/0002; A61F2230/0004; A61F2230/0006; A61F2230/0013; A61F2230/0063; A61F2230/0067; A61F2230/0069; A61F2310/00; A61F2310/00005; A61F2310/00365; A61L2300/00; A61L2300/20; A61L2300/23; A61L2300/236; A61L2300/252; A61L2300/40; A61L2300/404; A61L2300/406; A61L2300/412; A61L2300/414; A61L2430/00; A61L2430/06; A61L2430/38; Y; Y10; Y10S; Y10S623/00; Y10S623/901
Claims Analysis
Total Claims: 28
Claim 1
Independent Claim
189 words
A meniscal augmentation device for implantation into a segmental defect of a meniscus in a subject, the device comprising a plurality of biocompatible and at least partially bioresorbable fibers, wherein the segmental defect of the meniscus is a tear and the device is formed as a sheet sized to be inserted within the segmental defect of the meniscus, and the fibers are selected from the group consisting of a natural polymer, an analog of a natural polymer, a mixture of natural polymers, a mixture of analog polymers, and a mixture of a natural polymer and an analog polymer, wherein the device, when implanted into the segmental defect of the meniscus, establishes a biocompatible and an at least partially bioresorbable scaffold which comprises a dry, porous volume matrix having a pore size ranging from about 50 microns to about 500 microns and is adapted for the ingrowth of meniscal fibrochondrocytes, the scaffold and the ingrown meniscal fibrochondrocytes support natural meniscal load forces, and the in vivo outer surface of the composite of said meniscus and said device is substantially the same as that of a natural meniscus without segmental defects.
Claim 2
Dependent Claim
189 words
A meniscal augmentation device for implantation into a segmental defect of a meniscus in a subject, the device comprising a plurality of biocompatible and at least partially bioresorbable fibers, wherein the segmental defect of the meniscus is a tear and the device is formed as a sheet sized to be inserted within the segmental defect of the meniscus, and the fibers are selected from the group consisting of a natural polymer, an analog of a natural polymer, a mixture of natural polymers, a mixture of analog polymers, and a mixture of a natural polymer and an analog polymer, wherein the device, when implanted into the segmental defect of the meniscus, establishes a biocompatible and an at least partially bioresorbable scaffold which comprises a dry, porous volume matrix having a pore size ranging from about 50 microns to about 500 microns and is adapted for the ingrowth of meniscal fibrochondrocytes, the scaffold and the ingrown meniscal fibrochondrocytes support natural meniscal load forces, and the in vivo outer surface of the composite of said meniscus and said device is substantially the same as that of a natural meniscus without segmental defects.
Claim 3
Dependent Claim
22 words
The device of claim 1 wherein the matrix has a density of about 0.10 to about 0.25 gram matrix per cubic centimeter.
Claim 4
Dependent Claim
24 words
The device of claim 1 wherein the matrix has an intrafibrillary and interfibrillary space of about 2 to 25 cubic centimeters per gram matrix.
Claim 5
Dependent Claim
22 words
The device of claim 1 wherein the natural polymers are selected from the group of polymers derived from humans and non-human animals.
Claim 6
Dependent Claim
30 words
The device of claim 4 wherein the human-derived and non-human animal-derived polymers are selected from the group consisting of collagen, elastin, reticulin, cellulose, an analog thereof, and a mixture thereof.
Claim 7
Dependent Claim
10 words
The device of claim 5 wherein the polymer is collagen.
Claim 8
Dependent Claim
25 words
The device of claim 6 wherein the collagen is selected from the group consisting of Type I collagen, Type II collagen, and a combination thereof.
Claim 9
Dependent Claim
15 words
The device of claim 1 wherein at least a portion of the fibers are crossed.
Claim 10
Dependent Claim
19 words
The device of claim 1 further comprising a plurality of glycosaminoglycan molecules interspersed with the fibers of the matrix.
Claim 11
Dependent Claim
27 words
The device of claim 9 wherein at least a portion of the glycosaminoglycan molecules are crosslinked with at least a portion of the fibers of the matrix.
Claim 12
Dependent Claim
34 words
The device of claim 9 wherein the fibers are present at a concentration of about 75-100% by dry weight and the glycosaminoglycan molecules are present at a concentration of about 0-25% by dry weight.
Claim 13
Dependent Claim
33 words
The device of claim 9 wherein the glycosaminoglycan molecules are selected from the group consisting of chondroitin 4-sulfate, chondroitin 6-sulfate, keratan sulfate, derniatan sulfate, heparan sulfate, heparin, hyaluronic acid, and a mixture thereof.
Claim 14
Dependent Claim
15 words
The device of claim 8 wherein the crosslinks are formed by a chemical crosslinking agent.
Claim 15
Dependent Claim
15 words
The device of claim 10 wherein the crosslinks are formed by a chemical crosslinking agent.
Claim 16
Dependent Claim
33 words
The device of claim 13 wherein the crosslinking agent is selected from the group consisting of glutaraldehyde, formaldehyde, biocompatible bifunctional aldehydes, carbodiimides, hexamethylene diisocyanate, bis-imidates, polyglycerol polyglycidyl ether, glyoxal, and a mixture thereof.
Claim 17
Dependent Claim
33 words
The device of claim 14 wherein the crosslinking agent is selected from the group consisting of glutaraldehyde, formaldehyde, biocompatible bifunctional aldehydes, carbodiimides, hexamethylene diisocyanate, bis-imidates, polyglycerol polyglycidyl ether, glyoxal, and a mixture thereof.
Claim 18
Dependent Claim
11 words
The device of claim 15 wherein the crosslinking agent is formaldehyde.
Claim 19
Dependent Claim
11 words
The device of claim 15 wherein the crosslinking agent is glutaraldehyde.
Claim 20
Dependent Claim
11 words
The device of claim 16 wherein the crosslinking agent is formaldehyde.
Claim 21
Dependent Claim
11 words
The device of claim 16 wherein the crosslinking agent is glutaraldehyde.
Claim 22
Dependent Claim
10 words
The device of claim 1 further comprising a growth factor.
Claim 23
Dependent Claim
30 words
The device of claim 21 wherein the growth factor is transforming growth factor-α, transforming growth factor-β, fibroblast growth factor, epidermal growth factor, platelet derived growth factor, or a combination thereof.
Claim 24
Dependent Claim
10 words
The device of claim 1 further comprising an adhesion molecule.
Claim 25
Dependent Claim
17 words
The device of claim 23 wherein the adhesion molecule is fibronectin, chondronectin, osteonectin, or a combination thereof.
Claim 26
Independent Claim
202 words
A method for regenerating meniscal tissue in vivo, comprising: (a) obtaining a meniscal augmentation device for implantation into a segmental defect in a meniscus in a subject, the meniscal augmentation device comprising biocompatible and at least partially bioresorbable fibers, wherein the device has an outer surface contour substantially complementary to the segmental defect in the meniscus, and the fibers are selected from the group consisting of a natural polymer, an analog of a natural polymer, a mixture of natural polymers, a mixture of analog polymers, and a mixture of a natural polymer and an analog polymer, wherein the device is implantable into the segmental defect in the meniscus to establish a biocompatible and an at least partially bioresorbable scaffold which comprises a dry, porous volume matrix having a pore size ranging from about 50 microns to about 500 microns and is adapted for the ingrowth of meniscal fibrochondrocytes, and the scaffold and the ingrown meniscal fibrochondrocytes support natural meniscal load forces; and (b) implanting the device into the segmental defect in the meniscus in the subject whereby the in vivo outer surface of the composite of said device and said meniscus is substantially the same as natural meniscus without a segmental defect.
Claim 27
Independent Claim
202 words
A method for regenerating meniscal tissue in vivo, comprising: (a) obtaining a meniscal augmentation device for implantation into a segmental defect in a meniscus in a subject, the meniscal augmentation device comprising biocompatible and at least partially bioresorbable fibers, wherein the device has an outer surface contour substantially complementary to the segmental defect in the meniscus, and the fibers are selected from the group consisting of a natural polymer, an analog of a natural polymer, a mixture of natural polymers, a mixture of analog polymers, and a mixture of a natural polymer and an analog polymer, wherein the device is implantable into the segmental defect in the meniscus to establish a biocompatible and an at least partially bioresorbable scaffold which comprises a dry, porous volume matrix having a pore size ranging from about 50 microns to about 500 microns and is adapted for the ingrowth of meniscal fibrochondrocytes, and the scaffold and the ingrown meniscal fibrochondrocytes support natural meniscal load forces; and (b) implanting the device into the segmental defect in the meniscus in the subject whereby the in vivo outer surface of the composite of said device and said meniscus is substantially the same as natural meniscus without a segmental defect.
Claim 28
Dependent Claim
31 words
The method of claim 25, wherein the segmental defect of the meniscus is a tear and the device is formed as a sheet sized to be inserted into the segmental defect.
References Cited (Backward Citations)
US3443261A
Cited
US3551560A
Cited
US3855638A
Cited
US4085466A
Cited
US4280954A
Cited
US4060081A
Cited
GB1515963A
Cited
US4000525A
Cited
US4055862A
Cited
US4064567A
Cited
US4291013A
Cited
US4351069A
Cited
US4385404A
Cited
CA1170001A
Cited
US4378224A
Cited
US4344193A
Cited
US4400833A
Cited
US4350629A
Cited
US4502161B1
Cited
US4472840A
Cited
US4502161A
Cited
US4418691A
Cited
US4458678A
Cited
US4505266A
Cited
US4542539A
Cited
WO1983003536A1
Cited
US4544516A
Cited
US4589881A
Cited
US4578079A
Cited
US4661111A
Cited
US4801299A
Cited
US4448718A
Cited
US4614794A
Cited
US4789633A
Cited
US4627853A
Cited
EP0277678A1
Cited
US5007934A
Cited
US5158574A
Cited
US5681353A
Cited
US5116374A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2003-03-28 | 2003-09-27 | 2004-03-28 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2007-03-28 | 2007-09-27 | 2008-03-28 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2011-03-28 | 2011-09-27 | 2012-03-28 | $7700.00 | Window Closed / Lapsed |